NCT00544921已完成1 期
Phase 1 Study of Anti-glycation Agent GLY-230
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Glycadia
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects
研究概览
简要总结
To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Men age 18-55
- •Negative drug screen
- •Normal EKG, clinical chemistries, CBC, urinalysis, and
- •Give written informed consent
排除标准
- •Active concomitant serious medical or surgical disease,
- •Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Other)
250 mg
Experimental
干预措施: GLY-230 (Drug)
500 mg
Experimental
干预措施: GLY-230 (Drug)
750 mg
Experimental
干预措施: GLY-230 (Drug)
1000 mg
Experimental
干预措施: GLY-230 (Drug)
50 mg
Experimental
干预措施: GLY-230 (Drug)
100 mg
Experimental
干预措施: GLY-230 (Drug)
结局指标
主要结局
A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects
时间窗: October, 2005 to October, 2006
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed ConditionsHealthy VolunteersNCT05729386GC Biopharma Corp34
招募中
1 期
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting ConditionsHealthy VolunteersNCT05703984GC Biopharma Corp50
已完成
1 期
Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK TabletHealthyNCT00954304Hanmi Pharmaceutical Company Limited30
已完成
1 期
A Study of LY2409021 in Participants With Different Levels of Kidney FunctionRenal Insufficiency, ChronicKidney Failure, ChronicNCT01929109Eli Lilly and Company47
已完成
2 期
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical CancerLung NeoplasmsOvarian NeoplasmsCervix NeoplasmsRenal NeoplasmsNCT00069160National Cancer Institute (NCI)48